(Q34659974)

3 August 2017

title

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (English)

1 reference

3 August 2017

0 references

9

Huamin Wang

1 reference

3 August 2017

author name string

Kathleen K Christians

1

1 reference

3 August 2017

Susan Tsai

2

1 reference

3 August 2017

Anna Mahmoud

3

1 reference

3 August 2017

Paul Ritch

4

1 reference

3 August 2017

James P Thomas

5

1 reference

3 August 2017

Lauren Wiebe

6

1 reference

3 August 2017

Tracy Kelly

7

1 reference

3 August 2017

Beth Erickson

8

1 reference

3 August 2017

Douglas B Evans

10

1 reference

3 August 2017

Ben George

11

1 reference

3 August 2017

publication date

25 February 2014

1 reference

3 August 2017

1 reference

3 August 2017

volume

19

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

266-274

1 reference

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958454

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958454

Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958454

The added value of multidisciplinary care for patients with pancreatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958454

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958454

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958454

Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3958454

Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24569947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24569947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pancreaticoduodenectomy and vascular resection: persistent controversy and current recommendations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24569947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1634/THEONCOLOGIST.2013-0273

1 reference

3 August 2017

1 reference

3 August 2017

1 reference